EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy ( ATTLAS , KCSG ‐ LU19 ‐04) in EGFR / ALK ‐Mutated Non–Small‐Cell Lung Cancer

Eun Joo Kang, Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park und 12 weitere

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 16.11.2026. Verfasst von Eun Joo Kang und 23 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The phase 3 ATTLAS study demonstrated that atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP) improved progression‐free survival compared with pemetrexed‐carboplatin/cisplatin (PC) in EGFR/ALK‐mutated non–small‐cell lung cancer after tyrosine kinase inhibitor failure. We report patient‐reported quality of life (QoL) outcomes.

Methods

Patients received ABCP (atezolizumab 1200 mg, bevacizumab 15 mg/kg, carboplatin AUC 5–5.5, paclitaxel 175 mg/m 2 ) or PC (pemetrexed 500 mg/m 2 , carboplatin AUC 5.0, or cisplatin 70 mg/m 2 ) every 3 weeks. QoL was assessed using EORTC QLQ‐C30 and QLQ‐LC13. Primary endpoints were changes in global health status/QoL (GHS/QoL) from baseline at weeks 9 and 24, and median time to deterioration (TTD; ≥ 10‐point decline).

Results

Of 228 randomized patients (2:1), 146 (ABCP) and 68 (PC) completed ≥ 1 QoL assessment. Baseline GHS/QoL was comparable between arms. Early GHS and physical functioning scores were numerically lower with ABCP but stabilized by week 24, with no significant differences at week 9 (−4.66; p = 0.247) or week 24 (−7.39; p = 0.305). Toxicity‐related symptoms (neuropathy, alopecia, and pain) were more frequent with ABCP, whereas cancer‐related symptom improvements (cough, dyspnea, and hemoptysis) occurred in both arms without significant differences. Median TTD was 3.48 months (ABCP) versus 6.90 months (PC; p = 0.160).

Conclusions

Despite impairment in symptoms commonly associated with chemotherapy, no significant between‐group difference in overall QoL was detected between ABCP and PC. Stable GHS/QoL and improvement in cancer‐related symptoms were observed alongside appropriate toxicity management. Trial Registration The protocol was approved by the institutional review board of Samsung Medical Center (IRB no. 2019–03‐027) and participating centers ( ClinicalTrials.gov identifier: NCT03991403)

Zitieren

APA

Kang, E. J., Park, S., Kim, T. M., Han, J., Lee, G., Shim, B. Y., Lee, Y., Kim, S., Kim, I. H., Lee, S., Kim, Y. J., Park, J. H., Park, S., Lee, K. H., Kim, J. W., Shin, S., Ock, C., Nam, B., Lee, J., …, & Ahn, M. (2026). Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy ( ATTLAS , KCSG ‐ LU19 ‐04) in EGFR / ALK ‐Mutated Non–Small‐Cell Lung Cancer. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72405

Vancouver

Kang EJ, Park S, Kim TM, Han J, Lee G, Shim BY, et al. Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy ( ATTLAS , KCSG ‐ LU19 ‐04) in EGFR / ALK ‐Mutated Non–Small‐Cell Lung Cancer. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72405

BibTeX
@article{Kang2026,
  author = {Kang, Eun Joo and Park, Sehhoon and Kim, Tae Min and Han, Ji‐Youn and Lee, Gyeong‐Won and Shim, Byoung Yong and Lee, Yun‐Gyoo and Kim, Sang‐We and Kim, Il Hwan and Lee, Suee and Kim, Yu Jung and Park, Ji Hyun and Park, Sang‐Gon and Lee, Ki Hyeong and Kim, Ju Won and Shin, Seong‐Hoon and Ock, Chan‐Young and Nam, Byung‐Ho and Lee, Jaebong and Jung, Hyun Ae and Sun, Jong‐Mu and Lee, Se‐Hoon and Ahn, Jin Seok and Ahn, Myung‐Ju},
  title = {Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy ( ATTLAS , KCSG ‐ LU19 ‐04) in EGFR / ALK ‐Mutated Non–Small‐Cell Lung Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72405}
}
Kostenlos starten →